All of these genes have been associated with tumor growth and progression, and recent studies suggest that additional mutations in KRAS and NRAS, as well as downstream mutations in BRAF or PIK3CA, may cause resistance to anti-EGFR treatment [12]. The gene discussed is PIK3CA; the disease is neoplasm.